Special Report on Cyclopharm (ASX:CYC): FDA approval is last piece of the puzzle

Marc Kennis Marc Kennis, March 1, 2022

Cyclopharm

Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.

 

CYC is on of Marc & Stuart’s Top Picks. You can read the full report below!

 

 

 

Stay up-to-date on ASX-listed Life Sciences stocks!

Make sure you subscribe to Stocks Down Under today

 

GET A 30-DAY FREE TRIAL

 

No credit card needed and the trial expires automatically.

Recent Posts

coal be phased out in Australia

When will coal be phased out in Australia? And what will this mean for ASX coal and energy stocks?

When will coal be phased out in Australia? It is inevitable that coal’s days are numbered, although the Russia-Ukraine war…

Woolworths shares

Here are 5 reasons why Woolworths shares aren’t as great an investment as you might think

Woolworths shares may at first glance appear to be one of the most risk-free investments on the ASX. It has…

Australian merger and acquisition laws

Australian merger and acquisition laws will be overhauled in 2026. Is this good or bad for ASX stocks?

Last week, the government introduced changes Australian merger and acquisition laws not seen in nearly 5 decades. The ACCC had…